Navigation Links
Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
Date:2/25/2013

meHalozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Safe Harbor StatementIn addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the Company's expected net cash burn for 2013, the development and commercialization of products and the potential benefits and attributes of such products) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse event and competi
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
2. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
3. Halozyme to Host Third Quarter Financial Results Conference Call
4. Halozyme Reports Second Quarter 2012 Financial Results
5. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
6. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
7. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
8. Halozyme Reports First Quarter 2012 Financial Results
9. Halozyme to Host First Quarter 2012 Financial Results Conference Call
10. Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
11. Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/14/2014)... InformEx, North America,s leading business ... hold the 30 th edition of its annual conference ... from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... chemical and specialty chemical companies will take part in the ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/17/2014)... the April issue of Immunity , Kevin J. ... Research, says it,s time to take a fresh look ... sepsis, which kills millions worldwide every year, including more ... into the bloodstream to fight an injury or infection ... maintaining good health without inflammation, wounds and infections ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
(Date:4/17/2014)... 2014 By discovering a new mechanism that allows ... researchers at UC Irvine and the Salk Institute have ... or prevent stroke-induced brain damage. , A complex and ... death and primary reason for disability in the U.S. ... and lets blood-borne material into the brain, causing the ...
Breaking Medicine News(10 mins):Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... new study led by Fox Chase Cancer Center radiation ... scores determined by pathologists at Fox Chase Cancer Center ... scores from referring institutions. She presented the new ... Society for Radiation Oncology on Monday, October 3. ...
... busy," and "too complicated." These are the typical excuses ... they fail to use online error-reporting systems designed to ... Johns Hopkins investigators found instead that the most common ... trouble and embarrassment. Investigators e-mailed an anonymous survey ...
... the parents of women with polycystic ovary syndrome (PCOS) are more ... a hormonal disorder affecting about 10% of women of reproductive age. ... women and a leading cause of infertility. The study shows ... form of cardiovascular disease, and almost twice as likely to have ...
... severe 2009 H1N1 influenza who developed respiratory failure and were ... blood had a lower rate of in-hospital death than similar ... study appearing in JAMA . The study is being ... European Society of Intensive Care Medicine meeting in Berlin. ...
... HealthDay Reporter , TUESDAY, Oct. 4 (HealthDay News) -- ... fare just as well if they are released the same day ... new research shows. "[Discharging patients the same day] wasn,t ... Rao, lead author of a study appearing in the Oct. 5 ...
... News) -- ,Raw sewage contains thousands of undiscovered viruses, ... study suggests. Viruses are everywhere, but only about ... this study, researchers looked for the genetic signatures of ... and Africa. They detected the signatures of 234 known ...
Cached Medicine News:Health News:Fox Chase Gleason scores better predict prostate cancer's recurrence after radiation 2Health News:Fox Chase Gleason scores better predict prostate cancer's recurrence after radiation 3Health News:Survey reveals reasons doctors avoid online error-reporting tools 2Health News:Oxygenating system associated with lower risk of death for H1N1 patients with respiratory failure 2Health News:Oxygenating system associated with lower risk of death for H1N1 patients with respiratory failure 3Health News:Overnight Stay May Not Be Necessary for Stenting: Study 2Health News:Overnight Stay May Not Be Necessary for Stenting: Study 3Health News:Raw Sewage a New Frontier for Scientists 2
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
... KWIK-QC Slides have a positive and negative ... inoculation. With these slides, perform QC and ... enhance their education and training programs by ... interpretation, all on one slide! KWIK-QC slides ...
Microbiology QC Slides come with one or two droplets of an air-dried and methanol-fixed microorganism, or a single smear containing a designated microorganism population....
... Well Plate Capability The Equalizer 384 ... Equalizerexpandable and equal tip spacing, choice of two ... In addition, this model allows you to evenly ... and accessing many gels and for use with ...
Medicine Products: